Search hospitals > New York > Bronx
James J Peters VA Medical Center
Claim this profileBronx, New York 10468
Global Leader in Spinal Cord Injury
Global Leader in Peroneal Nerve Injury
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Lung Cancer
Conducts research for Prostatic Neoplasm
219 reported clinical trials
32 medical researchers
Summary
James J Peters VA Medical Center is a medical facility located in Bronx, New York. This center is recognized for care of Spinal Cord Injury, Peroneal Nerve Injury, Non-Small Cell Lung Cancer, Lung Cancer, Prostatic Neoplasm and other specialties. James J Peters VA Medical Center is involved with conducting 219 clinical trials across 284 conditions. There are 32 research doctors associated with this hospital, such as Gary Schwartz, MD, Susan E. Bates, Jill M Wecht, EdD, and Yeun-Hee A. Park.Area of expertise
1Spinal Cord Injury
Global LeaderC1
C2
C3
2Peroneal Nerve Injury
Global LeaderTop PIs
Gary Schwartz, MDNYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center1 year of reported clinical research
Studies Cancer
Studies Solid Tumors
14 reported clinical trials
37 drugs studied
Susan E. BatesJames J Peters VA Medical Center5 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
9 reported clinical trials
20 drugs studied
Jill M Wecht, EdDJames J. Peters VA Medical Center, Bronx, NY2 years of reported clinical research
Studies Spinal Cord Injury
Studies Low Blood Pressure
7 reported clinical trials
8 drugs studied
Yeun-Hee A. ParkJames J Peters VA Medical Center10 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
6 reported clinical trials
13 drugs studied
Clinical Trials running at James J Peters VA Medical Center
Lung Cancer
Spinal Cord Injury
Prostate Cancer
Post-Traumatic Stress Disorder
Non-Small Cell Lung Cancer
Suicide
Prostatic Neoplasm
Low Blood Pressure
Depression
Obsessive-Compulsive Disorder
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting2 awards Phase 34 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at James J Peters VA Medical Center?
James J Peters VA Medical Center is a medical facility located in Bronx, New York. This center is recognized for care of Spinal Cord Injury, Peroneal Nerve Injury, Non-Small Cell Lung Cancer, Lung Cancer, Prostatic Neoplasm and other specialties. James J Peters VA Medical Center is involved with conducting 219 clinical trials across 284 conditions. There are 32 research doctors associated with this hospital, such as Gary Schwartz, MD, Susan E. Bates, Jill M Wecht, EdD, and Yeun-Hee A. Park.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.